Live
FierceBiotechGilead cancels midstage HIV trial as FDA’s clinical hold remains intactEndpoints NewsGilead ends a Phase 2/3 trial of long-acting HIV pillsLonza NewsLonza releases annual report - The Vacaville ReporterBioPharma DiveBiogen, on the heels of a $5.6B buyout, turns its sights to early-stage assetsEndpoints NewsNoom plans push into peptides beyond weight loss drugsFierceBiotechThousands of clinical trial sites impacted by Middle East conflict: reportFierceBiotechDrug combo treats multiple cancers with ‘paradox’ mutation in miceFierceBiotechValneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole storyAgilentSynthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents - PR NewswireEndpoints NewsMaking custom CRISPR therapies could be harder than initially thoughtEndpoints NewsTo counter China, FDA chief wants to speed new drug trial processLonza NewsLonza Group (SWX:LONN) Is Up 5.8% After 25% Dividend Hike And Board Refresh - Has The Bull Case Changed? - simplywall.st

Archive

Latest Oldest
Total 7264
Page 343 / 404
Query --

Directory

59 All